arrow
Ø

Øivind Torkildsen

university of bergen
H指数:39
被引数:5,095

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Disease-modifying treatment does not influence severity and recovery of the first relapse after treatment onset in RRMS: insights from four large-scale clinical trials

疾病修正治疗不影响治疗开始后RRMS首次复发的严重程度和恢复:来自四项大规模临床试验的见解

2026-11-190
PRE
Intrathecal mesenchymal stem cell therapy in progressive multiple sclerosis: integrated blood and CSF profiling in the SMART-MS randomized trial

鞘内间充质干细胞疗法在进展性多发性硬化中的应用:SMART-MS随机试验中的血液和脑脊液综合分析

2026-09-290
OAAI
CD4+ T cells reactive to Epstein-Barr virus late lytic antigens are enriched in individuals with multiple sclerosis

CD4<sup>+</sup>T细胞在多发性硬化症患者中富集,并对EB病毒晚期溶细胞性抗原具有反应性

2026-07-150
PRE
Brain MRI findings in patients with post COVID-19 condition: frequency and longitudinal changes in a nationwide cohort study

COVID-19后状态患者的脑MRI发现:一项全国性队列研究中的频率和纵向变化

2025-11-180
OAAI
Non-inferiority of Rituximab versus OCrelizumab in Multiple Sclerosis (ROC-MS) – an Individual Participant Data Meta-Analysis

利妥昔单抗相较于奥瑞珠单抗在多发性硬化中的非劣效性(ROC-MS)——一项个体参与者数据meta分析

2025-11-110
OAAI
Haematopoietic stem cell transplant versus immune-reconstitution therapy in relapsing multiple sclerosis

造血干细胞移植与免疫重建疗法在复发型多发性硬化中的比较

Brain
IF11.7
2025-08-040
PRE
Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis
2024-03-271
PRE
The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis
2022-09-018
OAAI